Medlive Technology (02192) Releases Monthly Return for October 2025, Issued Shares Increase by 534,500

Bulletin Express

2025/11/04

Medlive Technology (02192) disclosed its Monthly Return for Equity Issuer for the period ended 31 October 2025. The company reported that its authorised share capital remained at 50,000,000,000 ordinary shares with a par value of USD 0.00001 each, amounting to a total of USD 500,000.

According to the filing, the total number of issued ordinary shares rose from 734,258,875 to 734,793,375. The increase of 534,500 shares resulted from the exercise of share options under the Pre-IPO Share Option Scheme, which raised RMB 203,110. The number of share options still available for exercise under the Post-IPO Share Option Scheme stands at 69,017,600 shares.

No changes to the number of treasury shares took place during the month. The company confirmed all necessary procedures and regulatory requirements for issuing the new shares have been fulfilled, and the newly issued ordinary shares rank pari passu in all respects with existing shares.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1179831478"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179831478\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179831478?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 17:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179831478","market":"hk","top_or_hot":-1,"title":"Medlive Technology (02192) Releases Monthly Return for October 2025, Issued Shares Increase by 534,500","media":"Bulletin Express","content":"<p>Medlive Technology (02192) disclosed its Monthly Return for Equity Issuer for the period ended 31 October 2025. The company reported that its authorised share capital remained at 50,000,000,000 ordinary shares with a par value of USD 0.00001 each, amounting to a total of USD 500,000.</p>\n<p>According to the filing, the total number of issued ordinary shares rose from 734,258,875 to 734,793,375. The increase of 534,500 shares resulted from the exercise of share options under the Pre-IPO Share Option Scheme, which raised RMB 203,110. The number of share options still available for exercise under the Post-IPO Share Option Scheme stands at 69,017,600 shares.</p>\n<p>No changes to the number of treasury shares took place during the month. The company confirmed all necessary procedures and regulatory requirements for issuing the new shares have been fulfilled, and the newly issued ordinary shares rank pari passu in all respects with existing shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medlive Technology (02192) Releases Monthly Return for October 2025, Issued Shares Increase by 534,500</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedlive Technology (02192) Releases Monthly Return for October 2025, Issued Shares Increase by 534,500\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2025-11-04 17:42</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Medlive Technology (02192) disclosed its Monthly Return for Equity Issuer for the period ended 31 October 2025. The company reported that its authorised share capital remained at 50,000,000,000 ordinary shares with a par value of USD 0.00001 each, amounting to a total of USD 500,000.</p>\n<p>According to the filing, the total number of issued ordinary shares rose from 734,258,875 to 734,793,375. The increase of 534,500 shares resulted from the exercise of share options under the Pre-IPO Share Option Scheme, which raised RMB 203,110. The number of share options still available for exercise under the Post-IPO Share Option Scheme stands at 69,017,600 shares.</p>\n<p>No changes to the number of treasury shares took place during the month. The company confirmed all necessary procedures and regulatory requirements for issuing the new shares have been fulfilled, and the newly issued ordinary shares rank pari passu in all respects with existing shares.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02192","symbol_name":"醫脈通","start_time":0,"source_url":"","article_id":"1179831478","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179831478","pubTimestamp":1762249352,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Medlive Technology (02192) disclosed its Monthly Return for Equity Issuer for the period ended 31 October 2025. The company reported that its authorised share capital remained at 50,000,000,000...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02192":"医脉通"},"translate_title":"Medlive Technology(02192)发布2025年10月月报表已发行股份增加53.45万股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02192":1},"content_text":"Medlive Technology (02192) disclosed its Monthly Return for Equity Issuer for the period ended 31 October 2025. The company reported that its authorised share capital remained at 50,000,000,000 ordinary shares with a par value of USD 0.00001 each, amounting to a total of USD 500,000.\nAccording to the filing, the total number of issued ordinary shares rose from 734,258,875 to 734,793,375. The increase of 534,500 shares resulted from the exercise of share options under the Pre-IPO Share Option Scheme, which raised RMB 203,110. The number of share options still available for exercise under the Post-IPO Share Option Scheme stands at 69,017,600 shares.\nNo changes to the number of treasury shares took place during the month. The company confirmed all necessary procedures and regulatory requirements for issuing the new shares have been fulfilled, and the newly issued ordinary shares rank pari passu in all respects with existing shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}